MX2012002677A - Forma farmaceutica oral, que consta de al menos un agente activo, sustancias auxiliares de formulacion y particulas magnetizables. - Google Patents

Forma farmaceutica oral, que consta de al menos un agente activo, sustancias auxiliares de formulacion y particulas magnetizables.

Info

Publication number
MX2012002677A
MX2012002677A MX2012002677A MX2012002677A MX2012002677A MX 2012002677 A MX2012002677 A MX 2012002677A MX 2012002677 A MX2012002677 A MX 2012002677A MX 2012002677 A MX2012002677 A MX 2012002677A MX 2012002677 A MX2012002677 A MX 2012002677A
Authority
MX
Mexico
Prior art keywords
dosage form
auxiliary substances
magnetizable particles
formulation auxiliary
active agent
Prior art date
Application number
MX2012002677A
Other languages
English (en)
Spanish (es)
Inventor
Rosario Lizio
Michael Gottschalk
Michael Damm
Norbert Windhab
Andreas Gryczke
Christian Meier
Benedikt Hartwig
Melanie Liefke
Juan Tome Alcade
Angela Olf
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of MX2012002677A publication Critical patent/MX2012002677A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883Capsule finishing, e.g. dyeing, aromatising, polishing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012002677A 2009-09-03 2010-08-30 Forma farmaceutica oral, que consta de al menos un agente activo, sustancias auxiliares de formulacion y particulas magnetizables. MX2012002677A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23961309P 2009-09-03 2009-09-03
DE102009029170 2009-09-03
PCT/EP2010/062641 WO2011026808A1 (en) 2009-09-03 2010-08-30 Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles

Publications (1)

Publication Number Publication Date
MX2012002677A true MX2012002677A (es) 2012-04-11

Family

ID=42984007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002677A MX2012002677A (es) 2009-09-03 2010-08-30 Forma farmaceutica oral, que consta de al menos un agente activo, sustancias auxiliares de formulacion y particulas magnetizables.

Country Status (13)

Country Link
US (1) US9050256B2 (https=)
EP (1) EP2473095B1 (https=)
JP (1) JP5868319B2 (https=)
KR (1) KR101731130B1 (https=)
CN (1) CN102573612B (https=)
BR (1) BR112012004967B8 (https=)
CA (1) CA2772708C (https=)
ES (1) ES2528494T3 (https=)
IL (1) IL217897A (https=)
MX (1) MX2012002677A (https=)
PL (1) PL2473095T3 (https=)
SI (1) SI2473095T1 (https=)
WO (1) WO2011026808A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140341983A1 (en) * 2011-09-14 2014-11-20 Donn M. Dennis Smart™ solid oral dosage forms
DE102011089334A1 (de) * 2011-12-21 2013-06-27 Evonik Röhm Gmbh Detektionssystem zur Erfassung magnetischer Objekte im menschlichen Organismus
US11667906B2 (en) * 2014-11-24 2023-06-06 Corning Incorporated Magnetic microcarriers
US11024449B2 (en) * 2017-06-06 2021-06-01 Apple Inc. Multipole elastomeric magnet with magnetic-field shunt
CA3084087A1 (en) 2017-12-04 2019-06-13 Evonik Operations Gmbh Masking and subsequently visualising esr signals using the combination of two materials
US10824822B2 (en) * 2019-02-05 2020-11-03 International Business Machines Corporation Magnetic tracking for medicine management
US10679018B1 (en) 2019-02-05 2020-06-09 International Business Machines Corporation Magnetic tracking for medicine management
JP7502741B2 (ja) * 2019-09-26 2024-06-19 スピンセンシングファクトリー株式会社 磁気マーカーおよび磁気マーカー検出システム
AU2021356684A1 (en) 2020-10-09 2023-05-11 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
CN112360304A (zh) * 2020-11-06 2021-02-12 炫丽建材江苏有限公司 一种适用于22度免拉手门板的自愈合封边工艺
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
JP2025512969A (ja) 2022-04-06 2025-04-22 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Her2陽性転移性乳がん及び他のがんを治療するための組成物及び方法
US20250250326A1 (en) 2022-04-06 2025-08-07 The Trustees Of The University Of Pennsylvania Passive immunization with anti-aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3723310A1 (de) * 1987-07-15 1989-01-26 John Urquhart Pharmazeutisches praeparat und verfahren zu seiner herstellung
DE3740187A1 (de) 1987-11-27 1989-06-08 Urquhart John Verfahren und vorrichtung zum ueberwachen und/oder kontrollieren und/oder registrieren und/oder anzeigen der einnahme von pharmazeutischen praeparaten
DE3940260A1 (de) 1989-03-04 1990-09-13 Werner Weitschies Verfahren zur bestimmung des aufenthaltsortes und der bewegung von objekten durch ihre markierung als magnetisches moment
CN1056049C (zh) 1994-02-02 2000-09-06 湖南省商业科技研究所 一种磁疗食品的制备方法
US6081734A (en) 1996-08-16 2000-06-27 Roche Diagnostics Gmbh Monitoring system for the regular intake of a medicament
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
EP1557151A1 (en) 2004-01-22 2005-07-27 F. Hoffmann-La Roche Ag Solid dosage form
CN100355454C (zh) * 2005-10-25 2007-12-19 南京工业大学 磁热疗用纳米磁粉-抗人肝癌单抗HAb18靶向药物
EP1880716A1 (en) 2006-07-19 2008-01-23 Sandoz AG Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
DE102008033662A1 (de) 2008-07-11 2010-01-14 Technische Universität Ilmenau Pharmakologische Darreichungsform und Vorrichtung und Verfahren zur kontinuierlichen Lokalisierung und Verfolgung des Auflösevorganges dieser

Also Published As

Publication number Publication date
JP2013503831A (ja) 2013-02-04
IL217897A0 (en) 2012-03-29
WO2011026808A1 (en) 2011-03-10
ES2528494T3 (es) 2015-02-10
CN102573612B (zh) 2015-07-08
JP5868319B2 (ja) 2016-02-24
EP2473095A1 (en) 2012-07-11
KR20120060210A (ko) 2012-06-11
US9050256B2 (en) 2015-06-09
US20120143039A1 (en) 2012-06-07
HK1168016A1 (en) 2012-12-21
BR112012004967A2 (pt) 2016-04-05
SI2473095T1 (sl) 2015-02-27
IL217897A (en) 2014-06-30
PL2473095T3 (pl) 2015-04-30
KR101731130B1 (ko) 2017-05-11
BR112012004967B1 (pt) 2021-05-11
CA2772708A1 (en) 2011-03-10
EP2473095B1 (en) 2014-11-12
CA2772708C (en) 2017-07-11
WO2011026808A8 (en) 2012-03-15
BR112012004967B8 (pt) 2022-07-05
CN102573612A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
MX2012002677A (es) Forma farmaceutica oral, que consta de al menos un agente activo, sustancias auxiliares de formulacion y particulas magnetizables.
IL274829B (en) A pharmaceutical preparation containing an echinocandin compound and the use of a freeze-dried preparation containing an echinocandin compound in the preparation of an aqueous solution for the treatment of a fungal infection
EA201400972A1 (ru) Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения
MX2020000984A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
IL232325A0 (en) 18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease
FR2967674B1 (fr) Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
WO2012121528A3 (en) Magnetic nanocomposite specific for thyroid cancer and use thereof
WO2012156317A3 (en) Intranasal pharmaceutical dosage forms comprising naloxone
IN2014MN02214A (https=)
BRPI0721148B8 (pt) nanopartículas magnéticas para aplicação em hipertermia, preparação destas e uso de construtos apresentando aplicação farmacológica
BR112013028365A2 (pt) "composição líquida compreendendo adi, composto compreendendo adi ligada covalentemente através de grupo de ligação a polietilenoglicol e uso de adi no preparo de composição para tratamento de câncer".
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
CL2012003168A1 (es) Composicion farmaceutica que comprende una solucion acuosa de minociclina y un cation divalente o trivalente en una proporcion mayor de 2:1 con respecto a la minociclina; metodo de preparacion; kit y uso en el tratamiento de infecciones bacterianas.
CL2012001940A1 (es) Composiciones que comprenden extractos de andrographis paniculata combinados con extractos de ginkgo biloba complejados con fosfolípidos; y su uso en la preparación de un medicamento para el tratamiento de alzheimer y esclerosis múltiple.
FR2958935B1 (fr) Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine
EP2666482A4 (en) PARTICLE COMPOSITION AND PHARMACEUTICAL COMPOSITION WITH PARTICLE COMPOSITION
BR112012016736A2 (pt) composição , formulação farmacêutica e uso da composição"
MX371209B (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
IN2014MN02156A (https=)
AR077483A1 (es) Sal de citrato del 9e-15-(2-pirrolidin -1-il-etoxi)-7,12,25-trioxa-19-21,24-triaza-tetraciclo (18-3.1.1(2,5).1(14,18) hexacosa-1 (24),2,4,9,14,16,18 (26),20,22- nonaeno
IN2014DN11097A (https=)
TN2011000352A1 (en) New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative
NZ608164A (en) Formulations for bovine granulocyte colony stimulating factor and variants thereof
Rongming Status of China Rare Earth Permanent Magnet Industry and Development Trend of the Technology
WO2014165842A3 (en) Nanoparticle formulations in biomarker detection

Legal Events

Date Code Title Description
FG Grant or registration